Compare Adaptive Biotechnologies Corp (ADPT) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Consumer Staples Select Sector SPDR Fund — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Consumer Staples Select Sector SPDR Fund trades at $84.39. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ADPT | XLP | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $90.00 |
52-Week Low | $10.24 | $75.61 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
XLP trades at $84.1, down 1.05% over the past day, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds a 100% buy rating from analysts and offers a 2.6% dividend yield, positioning it as a defensive play in consumer staples. Recent news highlights its role in portfolio diversification amid market volatility, with retail sales strength supporting the sector.
Outlook remains positive given analyst consensus and defensive characteristics, though risks include sector concentration and economic sensitivity. The ETF's low expense ratio and high yield appeal to income-focused investors, but competition from similar funds and macroeconomic pressures warrant monitoring for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
